Breast Cancer Deadlier in Women with Cosmetic Implants (06-7-2013)

Breast cancer appears to be more deadly among women with cosmetic breast implants, according to the results of a study published in the British Medical Journal—possibly because it is detected at a more advanced stage. Approximately 200,000 women are... Continue Reading

Avastin Doesn’t Improve Survival in Newly Diagnosed Glioblastoma (06-7-2013)

In a Phase III clinical trial among patients with newly diagnosed glioblastoma, the addition of Avastin® (bevacizumab) to standard chemoradiation increased side effects and did not improve overall survival. These results were presented at the 2013 Annual... Continue Reading

Ganetespib Promising for Advanced Lung Cancer (06-6-2013)

In a Phase II clinical trial, second-line treatment with a combination of chemotherapy and the investigational drug ganetespib improved overall survival among patients with advanced lung adenocarcinoma. These results were presented at the 2013 Annual... Continue Reading

BRAF V600E mutation Increases Death Risk in Papillary Thyroid Cancer (06-5-2013)

The presence of the BRAF V600E mutation is significantly associated with increased cancer-related death among patients with papillary thyroid cancer, according to the results of a study published in the Journal of the American Medical Association. The... Continue Reading

Genomic Testing with Oncotype DX Provides Prognostic Information in Stage IV Breast Cancer (06-4-2013)

Among women with Stage IV, estrogen receptor-positive breast cancer, the Oncotype DX® breast cancer test provided information about cancer prognosis; this may help guide treatment decisions. These results were presented at the 2013 Annual Meeting of... Continue Reading

Ibrutinib Active In Untreated, Relapsed and Unresponsive CLL (06-3-2013)

The drug ibrutinib was well tolerated and highly effective in patients with untreated, relapsed and unresponsive chronic lymphocytic leukemia—leading to large reductions in tumor burden, according to the results of a study presented at the American... Continue Reading

Rituxan May Prevent Need for Radiation in Mediastinal B-Cell Lymphoma (05-31-2013)

A dose-adjusted, infusion approach to aggressive chemotherapy with Rituxan® (rituximab) may allow patients with primary mediastinal B-cell lymphoma to skip radiation, according to the results of a study published in the New England Journal of Medicine. Non-Hodgkin’s... Continue Reading

Erbitux Plus Chemo Boosts Survival in Patients with Colorectal Cancer and Liver Metastases (05-29-2013)

Adding Erbitux® (cetuximab) to standard chemotherapy might allow some patients with colorectal cancer and inoperable liver metastases to undergo successful surgical resection of the liver metastasis, according to the results of a study published in the Journal... Continue Reading

Delayed Mammography Affects Breast Cancer Mortality in Women Over Age 75 (05-27-2013)

Older women with an extended period of time between their last mammogram and the diagnosis of breast cancer are at an increased risk of dying from the disease, according to the results of a study presented at the American Association for Cancer Research... Continue Reading

Antidepressant Cymbalta May Reduce Pain from Chemotherapy-Induced Peripheral Neuropathy (05-24-2013)

The antidepressant Cymbalta® (duloxetine) appears to reduce the numbness and tingling associated with taxane or platinum-based chemotherapy, according to the results of a study published in the Journal of the American Medical Association. Peripheral... Continue Reading

Breast-Conserving Therapy Comparable to Mastectomy for Women with Early-Stage Triple-Negative Breast Cancer (05-23-2013)

In a study of more than 600 women with early-stage triple-negative breast cancer treated at a single institution, treatment with breast-conserving therapy was as effective as total mastectomy. These results were published in Annals of Surgery Oncology. Breast-conserving... Continue Reading

Intermittent Zelboraf Treatment in Patients with Melanoma May Prevent Resistance to the Drug (05-22-2013)

Tumors resistant to Zelboraf® (vemurafenib) in patients with melanoma showed reduced growth after treatment was stopped. What’s more—animal models have shown that drug resistance was prevented by intermittent treatment. These results were presented... Continue Reading